HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma

This is a single-arm exploratory clinical study to evaluate the efficacy and safety of HAIC in combination with Sintilimab and Donafenib in patients with BCLC-C stage who have not received prior systemic therapy

Trial Details

NCT ID
NCT06244225
Phase
PHASE2
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Donafenib； Sintilimab； HAIC
Locations (sample)
  • Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

  • Written informed consent should be signed before implementing any trial-related procedures
  • ECOG PS scores 0-1
  • Histologically/cytologically confirmed HCC or cirrhosis meeting the clinical diagnostic criteria of HCC by American Association for the Study of Li…
  • Barcelona Clinic Liver Cancer (BCLC) stage C

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →